Agenda
Check this page for the latest program information. Speakers and their time slots are subject to change.
DIRECTIONS
Driving directions and a map of the campus can be found at http://www.hbs.edu/about/visit.html
THURSDAY EVENING
NOVEMBER 2, 2006
5:00 - 8:00 PM Thursday
Meredith Room, Spangler Center, HBS Campus
Badge Pick-Up (Note: there is no on-site registration.)
6:00 - 9:00 PM Thursday
Williams Room, Spangler Center
Welcome Reception and Dinner
In partnership with the students of HBS, HBS Healthcare Club
7:30 AM - 6:00 PM Friday
Meredith Room, Spangler Center, HBS Campus
Badge Pick-Up (Note: there is no on-site registration.)
7:30 AM - 8:45 AM Friday
Williams Room, Spangler Center
Continental Breakfast
8:45 - 9:00 AM Friday
Spangler Auditorium
Opening Remarks and Introduction:
Why We Need a Dialogue
Wolfgang Klietmann, MD, OPM 12
Vice President, Conference Co-Chair, HBS Health
9:00 - 9:45 AM Friday
Spangler Auditorium
Reinventing R&D in the Life Sciences Industry
Jean-Pierre Garnier, PhD
Chief Executive Officer, GlaxoSmithKline
Today's life sciences industry faces more challenges than ever before -- pricing pressures, pipeline pressures, patent expirations, the soaring cost of developing new drugs. How can a company differentiate itself? Through R&D productivity and R&D intensity -- discovering and developing more medicines, faster and better than the competition. To do so takes courage and conviction, and only the best companies will survive.
»back to top
9:45 - 10:30 AM Friday
Spangler Auditorium
Health Care and the Pharmaceutical Industry --
Where Do We Go From Here?
James C Mullen
President and CEO
Biogen Idec
The pharmaceutical and biotechnology industries have been the source of breakthrough medicines that have improved the quality of people’s lives around the world. However, in recent years there has been increasing focus on the risks associated with drug development and the cost of prescription drugs. There is a perpetual struggle between society’s desire for new and better therapeutics to treat chronic diseases and the cost that comes with that innovation. To improve the delivery of health care requires thoughtful collaboration among the industry, government leaders, the public and investors, and a discussion of the larger trends, challenges and opportunities on the horizon. Issues at the center of facilitating change and driving innovation include improving productivity in drug development, demonstrating the value of novel therapeutics, increasing globalization in the industry and cultivating talent through greater emphasis on science education.
10:30 - 11:00 AM Friday
Spangler Auditorium Break Area
Coffee Break/Networking
11:00 - 12:00 PM Friday
Spangler Auditorium
The Impact of Alliances in the Life Sciences Industry:
The Virtual Integrated Company (Panel Discussion)
Despite unprecedented scientific discoveries, pharmaceutical companies are struggling. Pipelines are disappointing, and R&D costs are soaring. One common response is to look outside for promising drugs, technologies and services. “More and more we have to rely on partners,” says John C. Lechleiter, CEO of Eli Lilly. Why? What’s wrong with the old model--and is the rush to forge alliances working any better? We’ll explore the trend, its implications, and its thorny details. How do companies find innovative potential partners? How do they best manage these alliances and avoid the many potential pitfalls? And how is this changing the industry?
12:00 - 1:15 PM Friday
Williams Room, Spangler Center
Luncheon, Concurrent with Dean's Address
Meet HBS's New Dean
Jay O. Light
Dean of the Faculty, Harvard Business School
1:30 - 2:30 PM Friday
Spangler Auditorium
Stem Cell Technology: Between Ethics and Politics
(Panel Discussion)
The stem cell is set to dominate popular awareness of science like the atom bomb did a generation ago. No area of science holds such immediate promise for treating disease and improving human lives as stem cell research. But no area of science also causes such fundamental ethical concern and such ferocious political conflict.
Where are the new discoveries taking us? How are they changing the legal and political landscape? How will America compete internationally? Stem cell science moves breakneck speed, and as it does, it provokes a redefinition of ethical standards. What are the arguments for and against the use of embryonic stem cells? Adult stem cells? How, as a society, do we balance our responsibilities to the unborn and the sick?
2:30 - 3:15 PM Friday
Spangler Auditorium
India: An Emerging Economic Superpower
Prithviraj Chavan
Minister of State, Prime Minister's Office, India
India is being heralded by economists and global business leaders alike as an emerging economic superpower. Propelled by robust economic growth, widespread economic reforms and a large, young, skilled and entrepreneurial workforce, India is poised to become a global powerhouse.
3:15 - 3:30 PM Friday
Break
3:30 - 4:50 PM Friday
Spangler Auditorium
India Goes Global
India’s strengths in the IT and BPO industries are well known. Less familiar is its strength in the healthcare industry. In fact, India has deep roots in the generic pharmaceutical industry, an ancient tradition of indigenous medicine, several centers of excellence in allopathic medicine, a growing pharmaceutical and biotechnology outsourcing industry, and nascent innovative R&D-based drug development. This two-part session provides a first-hand view into several healthcare sub-sectors.
Part 1: Industry Leaders
Industry leaders describe how India's opportunities and challenges turn their once domestic concerns into increasingly global enterprises.
5:00 - 6:00 PM Friday
Spangler Auditorium
India Goes Global
Part 2: Panel Discussion
Leaders discuss the “true grit” of globalization, including: How might Western and Indian companies work together so that each party contributes their core strengths and complements each other? Will India’s patent reforms allay IP concerns? And what will the future global pharma industry look like in the next 3 years and 5 years?
6:00 - 7:15 PM Friday
Williams Room, Spangler Center
Drinks and Hors d'Oeuvres
7:15 - 9:30 PM Friday
Williams Room, Spangler Center
7th Annual Alumni Healthcare Conference Dinner
SATURDAY
NOVEMBER 4, 2006
8:30 - 9:45 AM Saturday
Meredith Room, Spangler Center
Badge Pick-Up (Note: there is no on-site registration.)
8:30 - 9:45 AM Saturday
Williams Room, Spangler Center
Breakfast Roundtable Discussions
Roundtable Chair: Steven Wardell, MBA '00
HBS Health Industry Alumni Association
Attendees will choose roundtables according to their areas of interest, and will discuss a specific healthcare topic over breakfast.
10:00 - 10:45 AM Saturday
Spangler Auditorium
Success Story: How to Sell an $85 Million Company for $1.4 Billion Six Years Later
David A. Dodd, AMP 156
Former President, CEO & Director
Serologicals Corporation
An Interview by: Scott Hensley
Staff Journalist, The Wall Street Journal
During David Dodd's six-year leadership, Serologicals Corporation was transformed from a company valued at $85 million to an acquisition value by Millipore Corporation of $1.4 billion, completed on July 14, 2006. The acquisition value represents a 44.3% premium to the 1-year average stock price and transaction multiples of 4.8x LTM revenues and 19.4x LTM EBITDA, representing one of the highest acquisition premiums in life sciences over the past several years. The presentation will address how the transformation strategy was developed and successfully implemented.
10:45 - 11:00 AM Saturday
Coffee Break
11:00 - 12:15 AM Saturday
Aldrich 112
HBS Case Study: "Are Blockbusters Necessary?"
John Quelch, PhD
Professor HBS, Senior Associate Dean
Case: “The Medicines Company,” by Professor John Gourville
This case will be sent to those who register by October 1.
It is early 2001 and the Medicines Co. just received FDA approval to market Angiomax, a blood thinner to be used during angioplasties and heart procedures. It is intended to be a better alternative to Heparin, an 80-year-old drug that costs less then $10 per dose. The company believes it can sell Angiomax for a much higher price than Heparin--but how much more? Angiomax also represents the first of several drugs being developed under a rather unique business model. The company is in the business of "rescuing" drugs that other companies have given up on--i.e., they purchase or license the rights to drugs that other companies have halted development on, with the intent of completing the development process and bringing the drug to market. With the success of Angiomax, the company feels that this business model has been
validated.
How should Angiomax be positioned? As a specialized drug for high-risk coronary patients or as a general use drug for all coronary patients? What is the value of Angiomax? How should Angiomax be priced? How would you go about promoting hospital adoption of Angiomax? What do you think of The Medicine Company's business model?
12:30 - 2:15 PM Saturday
Williams Room, Spangler Center
Luncheon & Closing Remarks
©2006 Harvard Business School Health Industry Alumni Association
Conference Co-Chairs
Anula Jayasuriya, MD, MBA '93
Wolfgang Klietmann, MD, OPM 12, Vice President